

Name of the Issuer:	GPT Healthcare Limited	Last updated on	31-May-24
---------------------	------------------------	-----------------	-----------

1 Type of Issue (PO / FPO)	IPO
----------------------------	-----

2 Issue Size (Rs. Cr)	525.14
- Fresh Issue Size (Rs. Cr)	40.00
- Offer for Sale Component (Rs. Cr)	485.14
Source: Final Post Issue Report dated November 16, 2022	

3 Grade of issue along with name of the rating agency	
Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)	6.2600*
Source: Final Post Issue Report dated March 5, 2024	
*The above figure is after technical rejections, multiple or duplicate bids and bids not banked/returned	

5 OIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
Particulars	%
(i) allotment in the issue	17.20%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (February 29, 2024)	12.81%
(iii) at the end of 1st FY (March 31, 2024) <sup>(1)</sup>	12.81%
(iv) at the end of 2nd FY (March 31, 2025) <sup>(2)</sup>	Not Available
(v) at the end of 3rd FY (March 31, 2026) <sup>(3)</sup>	Not Available
*Period not completed	
<sup>(1)</sup> Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024	

6 Financials of the issuer			
	(In Rs. Crore)		
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025) <sup>(1)</sup>	3rd FY (March 31, 2026) <sup>(2)</sup>
Income from operations	400.15	Not Available	Not Available
Net Profit for the period	47.77	Not Available	Not Available
Paid-up equity share capital	82.06	Not Available	Not Available
Reserves excluding revaluation reserves	1,364.35	Not Available	Not Available
*Period not completed			

7 Trading Status in the scrip of the issuer	
Company's Equity Shares are listed on both the BSE Limited and NSE. The Shares have not been suspended or delisted.	
Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025) <sup>(1)</sup>	Not Available
(iii) at the end of 3rd FY (March 31, 2026) <sup>(2)</sup>	Not Available
*Period not completed	

8 Change in Directors of issuer from the disclosures in the offer document		
Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	a) Mr. Dwarka Prasad Tanti b) Mr. Anurag Tanti	Re-appointment
(ii) at the end of 2nd FY (March 31, 2025) <sup>(1)</sup>	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026) <sup>(2)</sup>	Not Available	Not Available
Source: Stock Exchange Filings		
*Period not completed		

9 Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds			
(i) as disclosed in the offer document			
	(In Rs. Crore)		
Particulars	Amount proposed to be funded from Net Proceeds	Estimated Deployment (Financial Year 2024)	Estimated Deployment (Financial Year 2025)
Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	30.00	20.00	10.00
General Corporate Purposes	7.52	4.52	3.00
Source: Prospectus dated February 26, 2024			
(ii) Actual utilization			
	(In Rs. Crore)		
Particulars	As of March 31, 2024		
Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	573.40		
General Corporate Purposes	7.52		
* Source: Stock Exchange Intimation of statement of deviation/ variation dated May 21, 2024			
(iii) Reasons for deviation, if any	Not applicable		

11 Comments of monitoring agency, if applicable <sup>(1)</sup>	
(a) Comments on use of funds	Not Applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other observations expressed by the monitoring agency about the end use of funds	
* Monitoring Agency is not applicable since the fresh issue size is less than Rs. 100 crores	

12 Pricing Data	
Issue Price (Rs.):	186
Designated Stock Exchange:	BSE
Listing Date:	29-Feb-24

Price parameters	At close of listing day (Feb 29, 2024)	At close of 30th calendar day from listing day (Mar 29, 2024) <sup>(1)</sup>	At close of 90th calendar day from listing day (May 28, 2024) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2024) <sup>(3)(4)</sup>			As at the end of 2nd FY after the listing of the issue (March 31, 2025) <sup>(5)(6)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2026) <sup>(7)(8)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	200.75	176.45	147.55	176.45	219.70	199.80	Not available	Not available	Not available	Not available	Not available	
BSE SENSEX	72,690.30	73,651.35	75,170.65	74,651.26	74,245.17	71,674.42	Not available	Not available	Not available	Not available	Not available	
BSE HEALTHCARE <sup>(9)</sup>	35,079.32	36,052.84	35,662.18	35,052.84	35,342.21	33,389.29	Not available	Not available	Not available	Not available	Not available	

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days. Since 90th calendar day is a Saturday, the next trading day is considered.

(3) High and Low based on intra day prices.

(4) Pricing data not disclosed as the relevant fiscal year and period have not completed.

(5) BSE HEALTHCARE index represents the relevant sectoral index.

(6) Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024.

(7) In case of reporting date falling on a trading holiday, values for the trading day immediately preceding the trading holiday has been considered.

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	1st FY (March 31, 2024)	2nd FY (March 31, 2025) <sup>(2)</sup>	3rd FY (March 31, 2026) <sup>(3)</sup>
EPS	<b>Issuer:</b>			
	Basic	4.88	43.29	Not Available
	<b>Peer Group:</b>			
	Global Health Limited	12.58	52.04	Not Available
	Krishna Institute of Medical Sciences Limited	42.03	29.41	Not Available
	Jupiter Life Line Hospitals Limited	13.95	28.65	Not Available
	Yashwanth Hospital & Trauma Care Services Limited	10.09	14.46	Not Available
	Kova Medical Center & Hospital Limited	105.80	164.25	Not Available
	Shabhy Limited	6.31	9.67	Not Available
	<b>Industry Avg:</b>	<b>Not Applicable</b>	<b>Not Applicable</b>	<b>Not Applicable</b>
PE	<b>Issuer:</b>			
	Basic	NA	9.26	Not Available
	<b>Peer Group:</b>			
	Global Health Limited	90.29	17.58	Not Available
	Krishna Institute of Medical Sciences Limited	49.51	69.98	Not Available
	Jupiter Life Line Hospitals Limited	81.73	41.81	Not Available
	Yashwanth Hospital & Trauma Care Services Limited	37.66	28.86	Not Available
	Kova Medical Center & Hospital Limited	29.93	22.78	Not Available
	Shabhy Limited	49.01	24.75	Not Available
	<b>Industry Avg:</b>	<b>56.36</b>	<b>34.29</b>	<b>Not Applicable</b>
RoNW (%)	<b>Issuer:</b>			
	Basic	23.77	16.70	Not Available
	<b>Peer Group:</b>			
	Global Health Limited	13.56	5.15	Not Available
	Krishna Institute of Medical Sciences Limited	20.35	12.61	Not Available
	Jupiter Life Line Hospitals Limited	19.94	15.11	Not Available
	Yashwanth Hospital & Trauma Care Services Limited	36.06	17.94	Not Available
	Kova Medical Center & Hospital Limited	16.11	20.23	Not Available
	Shabhy Limited	7.33	14.90	Not Available
	<b>Industry Avg:</b>	<b>Not Applicable</b>	<b>Not Applicable</b>	<b>Not Applicable</b>
NAV per share	<b>Issuer:</b>			
	Basic	20.54	230.74	Not Available
	<b>Peer Group:</b>			
	Global Health Limited	89.65	326.88	Not Available
	Krishna Institute of Medical Sciences Limited	206.47	233.31	Not Available
	Jupiter Life Line Hospitals Limited	64.70	178.16	Not Available
	Yashwanth Hospital & Trauma Care Services Limited	27.84	101.78	Not Available
	Kova Medical Center & Hospital Limited	656.65	815.17	Not Available
	Shabhy Limited	85.54	98.90	Not Available
	<b>Industry Avg:</b>	<b>Not Applicable</b>	<b>Not Applicable</b>	<b>Not Applicable</b>

**Notes:**  
 (1) Sourced from Prospectus dated Feb-26, 2024.  
 (2) Period not over  
 Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:  
 (i) EPS (Rs) is Profit after tax attributable to equity shareholders for the year divided by Weighted average number of Equity Shares outstanding during the year / period  
 (ii) P/E - Closing Market Price as of relevant fiscal year end or period / EPS  
 (iii) RoNW - Return on net worth % is computed as net profit after tax attributable to owners of the holding company divided by net-worth excluding non controlling interest  
 (iv) NAV per share - NAV is computed as net worth divided by number of equity shares outstanding.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
17 March 2024	Search operation was carried out by Income Tax Department on the locations of the Company from March 14, 2024 to March 17, 2024. We hereby inform that all stock of inventory, cash and other assets were found to be duly recorded and no unaccounted cash or transactions have been found by the authorities. The search team has not seized anything incriminating.
19 March 2024	- Approval of unaudited financial results along with Limited Review Report for the quarter and nine months ended Dec 31, 2023 - Appointment of Mr. Vishal Goyal as Group COO and to be considered as SMP w.e.f. April 1, 2024
19 March 2024	Declared second Interim Dividend at the rate of 10% (Rs. 1.00 per share) on the face value of the equity shares (Rs. 10/- each) of the Company, for the financial year 2023-24. The Company is expecting to pay the interim dividend to the shareholders on or before April 17, 2024. The Record Date for the purpose of payment of the aforesaid Interim Dividend has been fixed at Monday, April 01, 2024
19 March 2024	Declared the list of KMPs who will determine materiality of any event or information, going forward: - Mr. Anurag Tanti - Mrs. Kirti Tanti - Mr. Anur Sharma
19 March 2024	In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Investor Presentation for Q3FY24 was submitted for dissemination to general public and investors.
19 March 2024	Record Date for Payment of Dividend revised to April 02, 204 from April 01, 2024
09 April 2024	Postal Ballot Notice for passing special resolution for continuation of Mr. Dwanika Prasad Tanti as Chairman and Wholetime Director of the Company after attaining the age of 75 years
16 April 2024	Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 issued by Practicing Company Secretary for the year ended March 31, 2024
16 April 2024	In terms of SEBI Circular No. SEBI/HO/DDSC/IRP/2018/144 dated November 26, 2018 with regard to fund raising by issuance of debt securities by large entities, Company does not fall under "Large Corporate" (LC) category as per the framework provided in the aforesaid circular. Therefore, the requirement of filing the initial disclosure and annual disclosure in Annexures A and B1 & B2 respectively to the aforesaid Circular does not arise.
25 April 2024	Pursuant to Regulation 30 read with Part A of Schedule I of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that Dr. Bharati Chattopadhyay, Chief Operating Officer of our Agarbala Hospital part of the Senior Management of the Company has resigned due to personal reasons.
25 April 2024	In continuation of Memorandum of Understanding Letter of Intent dated January 16, 2023, which forms part of Material Contracts and Documents of the Company, disclosed at the time of initial public offer of the Company, entered among Sun and Sun Inframetric Private Limited, Mosaic Infraventure Private Limited and our Company as GPT Healthcare Limited. Please be informed that our Company has further entered into Lease Agreement with Sun and Sun Inframetric Private Limited and Mosaic Infraventure Private Limited on April 24, 2024.
26 April 2024	The CR of the Company has changed from U70101WB1899PLD047402 to L170101WB1899PLD047402 by the Registrar of Companies, Kolkata, West Bengal
10 May 2024	Voting Results & Submission of Statutory Report for Postal Ballot for continuation of Mr. Dwanika Prasad Tanti as Chairman and Whole Time Director of the Company upon attaining the age of 75 years
14 May 2024	Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 21, 2024 at the Registered Office of the Company, inter-alia, to consider and approve following matters: a) the Audited Financial Results along with Report of the Statutory Auditors thereon of the Company for the 4th quarter and year ended on March 31, 2024 b) the recommendation of final dividend, if any, on the equity share capital of the company for the FY 2023-24 <a href="https://www.secdisclosure.com/announcements">https://www.secdisclosure.com/announcements</a> c) Declaration of unmodified opinion by statutory auditors in their Auditors Report on the annual audited standalone financial results for the quarter and year ended March 31, 2024 d) Declaration of unmodified opinion by statutory auditors in their Auditors Report on the annual audited standalone financial results for the quarter and year ended March 31, 2024 e) Approved convening of 35th Annual General Meeting on Thursday, July 25, 2024 through Video Conferencing (VC) f) Recommended Final Dividend of 15% i.e. Rs. 1.5 per equity share on the face value of Rs. 10 each for the financial year ended March 31, 2024 g) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Friday, July 19, 2024 to Thursday, July 25, 2024 (both days inclusive) for the purpose of 35 <sup>th</sup> Annual General Meeting and Dividend for the financial year 2023-24. The record (cut-off) date is Thursday, July 16, 2024 h) Approved the appointment of S.R. Buttoo & Co LLP, Chartered Accountants i) Approved the reappointment of Ashok Kumar Daga as the Secretarial Auditors of the Company for FY 2024-25 j) Approved the reappointment of S.K. Shrivastava Associates as the Cost Auditors of the Company for FY 2024-25, subject to ratification of their remuneration of the shareholders of the Company. k) Approved the reappointment of Sumit Binani & Associates, Chartered Accountants and ARV & Associates, Chartered Accountants, as Internal Auditors of the Company for the FY 2024-25 l) Approved resignation of the following Directors, based on the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders in the ensuing 35th Annual General Meeting of the Company: - Mr. Dwanika Prasad Tanti as Chairman and Whole Time Director for further period of 3 consecutive years w.e.f. Oct 1, 2024 - Mr. Anurag Tanti as Whole Time Director designated as the Executive Director for further period of 3 years w.e.f. Oct 1, 2024 m) Approved payment of Director Consultancy Fees to Dr. Gharshyam Goyal, Non-Executive Non-Independent Director of the Company for FY 2024-25 n) Approved revision in remuneration payable to Mrs. Kirti Tanti, Chief Financial Officer, a relative of Mr. Dwanika Prasad Tanti, Chairman of the Company, for <a href="https://www.secdisclosure.com/announcements">https://www.secdisclosure.com/announcements</a>
23 May 2024	Annual Secular Compliance Report issued by Practicing Company Secretary for the year ended March 31, 2024, pursuant to Circular No. CIR/CFD/CMD/27/2019 dated February 8, 2019 issued by Securities and Exchange Board of India read with Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Notes:**  
 The Company invites Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.  
 For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and/ or [www.nseindia.com](http://www.nseindia.com)

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/ or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.